<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798276</url>
  </required_header>
  <id_info>
    <org_study_id>ICOR-2016-01</org_study_id>
    <nct_id>NCT02798276</nct_id>
  </id_info>
  <brief_title>Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar: The AGTP II Trial</brief_title>
  <acronym>AGTP II</acronym>
  <official_title>Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar: The AGTP II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antoni Bayés Genís</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the efficacy of a pericardial adipose graft
      transposition (Adipose Graft Trasposition Procedure, AGTP) for the improvement of cardiac
      function in patients with a chronic myocardial infarction. Preclinical studies in the porcine
      model of myocardial infarction have shown that the AGTP reduces infarct area and improves
      cardiac function. A first-in-man clinical (NCT01473433) trial showed that the AGTP is safe in
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in necrotic mass ratio (%) by gadolinium retention.</measure>
    <time_frame>0-3-12 months</time_frame>
    <description>necrotic mass ratio (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in regional contractibility by NMR</measure>
    <time_frame>0-3-12 months</time_frame>
    <description>regional contractibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional parameters by Nuclear Magnetic Resonance: ventricular ejection fraction</measure>
    <time_frame>0-3-12 months</time_frame>
    <description>Left Ventricular Ejection Fraction, Right Ventricular Ejection Fraction (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional parameters by Nuclear Magnetic Resonance: ventricular volumes</measure>
    <time_frame>0-3-12 months</time_frame>
    <description>LVESV, LVEDV, RVESV, RVEDV (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional parameters by NMR: Cardiac output</measure>
    <time_frame>0-3-12 months</time_frame>
    <description>L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of natriuretic peptides</measure>
    <time_frame>0-1 week-3-12 months</time_frame>
    <description>NTproBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia by 24-h Holter</measure>
    <time_frame>0--3-12 months</time_frame>
    <description>Aupraventricular and ventricular arrhytmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death or re-admission</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause death or &gt;24h re-hospitalization due to all-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death or re-admission</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular death or &gt;24h re-hospitalization due to cardiovascular causes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in infarct size: left ventricular necrotic mass</measure>
    <time_frame>0-3-12 months</time_frame>
    <description>grams</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>AGTP-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in which the non-revascularizable area will be covered by the adipose graft and the revascularizable area will be treated with the normal procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in with the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AGTP-treatment</intervention_name>
    <description>Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).</description>
    <arm_group_label>AGTP-treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age, capable of giving informed consent.

          -  Q wave in the ECG

          -  Myocardial infarct &gt;=50% transmularity by NMR non revascularizable (for transmurality
             or bad vessel).

          -  Candidate to bypass for other myocardial areas

        Exclusion Criteria:

          -  Severe non cardiac co-morbidity with a reduction of life expectancy of less than 1
             year

          -  Severe valvular disease candidate for surgical restoration

          -  Candidate to ventricular remodeling

          -  Contraindication for NMR

          -  Severe renal or hepatic failure

          -  Abnoraml laboratory tests (no explanation at inclusion)

          -  Previous cardiac intervention

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pablo Avanzas</last_name>
      <phone>0034 985108000</phone>
    </contact>
    <investigator>
      <last_name>Pablo Avanzas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Germans Trias University Hospital; Germans Trias Research Institute</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paloma Gastelurrutia</last_name>
      <phone>0034 934978670</phone>
      <email>pgastelurrutia@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pol Gomez</last_name>
      <phone>0034 934978662</phone>
      <email>grupicrec@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antoni Bayes-Genis, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paloma Gastelurrutia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Lupon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Luisa Cámara, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolás Manito</last_name>
      <phone>0034 932607500</phone>
    </contact>
    <investigator>
      <last_name>Nicolás Manito, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pablo García Pavía</last_name>
      <phone>0034 911916000</phone>
    </contact>
    <investigator>
      <last_name>Pablo García Pavía, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julio Hernández</last_name>
      <phone>0034 922602000</phone>
    </contact>
    <investigator>
      <last_name>Julio Hernández Afonso, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Llorens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zulaika Grille</last_name>
      <phone>0034 981178000</phone>
    </contact>
    <investigator>
      <last_name>María G Crespo Leiro, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Bustamante Munguira</last_name>
      <phone>0034 972940200</phone>
      <email>jbustamantemunguira@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Bustamante Munguira</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramón Brugada</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastián Consulta de Investigación Cardiología</last_name>
      <phone>0034 915868000</phone>
    </contact>
    <investigator>
      <last_name>Francisco Fernández Avilés, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Teresa Pérez Martínez</last_name>
      <phone>0034 968369500</phone>
    </contact>
    <investigator>
      <last_name>Domingo Pascual Figal, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Jiménez Navarro</last_name>
      <phone>0034 951032000</phone>
    </contact>
    <investigator>
      <last_name>Eduardo de Teresa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julio Núñez</last_name>
      <phone>0034 961973500</phone>
    </contact>
    <investigator>
      <last_name>Julio Núñez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis H Varela Falcón</last_name>
      <phone>0034 983420000</phone>
    </contact>
    <investigator>
      <last_name>Alberto San Román</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bayes-Genis A, Gálvez-Montón C, Prat-Vidal C, Soler-Botija C. Cardiac adipose tissue: a new frontier for cardiac regeneration? Int J Cardiol. 2013 Jul 15;167(1):22-5. doi: 10.1016/j.ijcard.2012.05.082. Epub 2012 Jun 17. Review.</citation>
    <PMID>22709728</PMID>
  </reference>
  <reference>
    <citation>Gálvez-Montón C, Prat-Vidal C, Roura S, Soler-Botija C, Llucià-Valldeperas A, Díaz-Güemes I, Sánchez-Margallo FM, Bayes-Genis A. Post-infarction scar coverage using a pericardial-derived vascular adipose flap. Pre-clinical results. Int J Cardiol. 2013 Jun 20;166(2):469-74. doi: 10.1016/j.ijcard.2011.11.019. Epub 2011 Dec 2.</citation>
    <PMID>22137092</PMID>
  </reference>
  <reference>
    <citation>Gálvez-Montón C, Prat-Vidal C, Roura S, Farré J, Soler-Botija C, Llucià-Valldeperas A, Díaz-Güemes I, Sánchez-Margallo FM, Arís A, Bayes-Genis A. Transposition of a pericardial-derived vascular adipose flap for myocardial salvage after infarct. Cardiovasc Res. 2011 Sep 1;91(4):659-67. doi: 10.1093/cvr/cvr136. Epub 2011 May 16.</citation>
    <PMID>21576133</PMID>
  </reference>
  <reference>
    <citation>Bayes-Genis A, Gastelurrutia P, Cámara ML, Teis A, Lupón J, Llibre C, Zamora E, Alomar X, Ruyra X, Roura S, Revilla A, San Román JA, Gálvez-Montón C. First-in-man Safety and Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar. EBioMedicine. 2016 May;7:248-54. doi: 10.1016/j.ebiom.2016.03.027. Epub 2016 Apr 10.</citation>
    <PMID>27322478</PMID>
  </reference>
  <reference>
    <citation>Ma H, Liu J, Qian L. Fat for fostering: Regenerating injured heart using local adipose tissue. EBioMedicine. 2016 May;7:25-6. doi: 10.1016/j.ebiom.2016.03.024. Epub 2016 Mar 20.</citation>
    <PMID>27322455</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Antoni Bayés Genís</investigator_full_name>
    <investigator_title>Antoni Bayes-Genis, Chief of the Cardiology Service</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Cardiac regeneration</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

